View : 13 Download: 0

Current perspectives on therapeutic antibodies

Title
Current perspectives on therapeutic antibodies
Authors
Yoon S.Kim Y.-S.Shim H.Chung J.
Ewha Authors
심현보
SCOPUS Author ID
심현보scopus
Issue Date
2010
Journal Title
Biotechnology and Bioprocess Engineering
ISSN
1226-8372JCR Link
Citation
vol. 15, no. 5, pp. 709 - 715
Indexed
SCIE; SCOPUS; KCI WOS scopus
Abstract
Since the first monoclonal antibody, muromonab-CD3, was approved for therapeutic use in 1986, numerous molecules have been targeted using therapeutic antibody technology, resulting in 26 therapeutic antibodies being approved by the US FDA as of November, 2009. Initial concerns regarding antibody drugs focused on immunogenicity, short serum half-life, and weak efficacy. As the types of antibodies progressed from murine to chimeric, humanized, and fully human antibodies, great progress has been made in immunogenicity and in vivo instability issues. For example, humanized antibodies, such as bevacizumab, exhibit less than 0.2% immunogenicity and a 20 day serum half-life, which is comparable to native immunoglobulin. Some recently developed antibodies are exceedingly efficacious and have become first-line therapy for their target diseases. Here, we address and analyze all clinically approved therapeutic antibodies to date by discussing immunogenicity, half-life, and efficacy. © 2010 The Korean Society for Biotechnology and Bioengineering and Springer-Verlag Berlin Heidelberg.
DOI
10.1007/s12257-009-3113-1
Appears in Collections:
일반대학원 > 바이오융합과학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE